Blocking Anandamide Breakdown Eliminated Migraine-Like Pain in Mice | Research

The takeaway

Mice lacking the FAAH enzyme (which breaks down anandamide) were completely protected from nitroglycerin-induced migraine pain, and two FAAH-inhibiting drugs reproduced this protection through CB1 receptors.

Read this if you experience migraines and are interested in how the endocannabinoid system relates to migraine pain.

Complete abolition of migraine-like pain in FAAH-deficient mice

What the researchers found

Researchers used a nitroglycerin-induced migraine model in mice to test whether the endocannabinoid system could be targeted for migraine treatment. Mice genetically lacking FAAH, the enzyme that degrades anandamide, showed complete abolition of both mechanical allodynia (pain from gentle touch) and trigeminal neuron activation.

Two structurally different FAAH inhibitors (URB597 and PF3945) dose-dependently blocked the same pain responses in normal mice. The CB1 antagonist rimonabant completely reversed these protective effects, confirming the mechanism works through CB1 receptors.

Mice lacking CB1 or CB2 receptors, or the 2-AG-degrading enzyme MAGL, did not show the same protection, pinpointing FAAH and the anandamide/CB1 pathway as the critical target.

Why it matters

Migraine is a major cause of disability, and current treatments have significant limitations. Identifying FAAH inhibition as a potential migraine target opens a new therapeutic avenue that leverages the body's own pain-control system without the psychoactive effects of THC.

The numbers in context

Complete abolition of allodynia in FAAH knockout mice; both URB597 and PF3945 dose-dependently blocked pain; effects completely reversed by rimonabant; MAGL knockout showed no protection

How the study worked

Used genetic knockout mice (FAAH, MAGL, CB1, CB2) and two FAAH inhibitors (URB597 and PF3945) in a nitroglycerin-induced migraine model. Measured mechanical allodynia and trigeminal nucleus neuron activation. Verified receptor mechanisms with antagonist studies.

What this study cannot tell us

Mouse migraine model may not fully replicate human migraine. FAAH inhibitors have had setbacks in clinical development (safety concerns in a different context). Acute pain model may not reflect chronic or episodic migraine patterns.

How to read the evidence

Rigorous animal study using both genetic and pharmacological approaches with clear mechanistic confirmation, but translation to human migraine treatment remains uncertain.

When this study was published

Published in 2015. FAAH inhibitor development has faced clinical challenges unrelated to migraine.

The bigger picture

Migraine patients have shown altered endocannabinoid levels and FAAH activity. This study provides a mechanistic basis for targeting the anandamide pathway specifically, which could lead to non-psychoactive cannabinoid-based migraine treatments.

Questions still open

Can FAAH inhibitors be safely developed for human migraine treatment? Would they work for all migraine subtypes? How do these findings relate to anecdotal reports of cannabis helping with migraines?

Common questions

Could this lead to a new migraine treatment?

The data strongly supports FAAH as a migraine target. However, FAAH inhibitor clinical development has faced safety challenges in other contexts, and human migraine trials would be needed to confirm efficacy.

Is this why some people say cannabis helps their migraines?

Possibly. THC activates CB1 receptors, which is the same pathway this study identified as protective. However, THC is a less precise tool than FAAH inhibitors, which boost the body's own anandamide at the sites where it is needed.

Read the original research

Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 25(8), 1388-96

View on PubMed ↗Publisher’s paper ↗

Citation

Nozaki, Chihiro; Markert, Astrid; Zimmer, Andreas. (2015). Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 25(8), 1388-96. https://doi.org/10.1016/j.euroneuro.2015.04.001